Cardio-onco-hematología laboral. Protocolización coordinada. Documento de Consenso / Labor cardio-onco-hematology. Coordinated protocolization. Consensus Document

Las Enfermedades cardiovasculares y el cáncer comparten factores de riesgo y son las principales causas de mortalidad y morbilidad en nuestro medio. De otro lado, el concepto cardiotoxicidad hace referencia a desarrollo de patologías cardiovasculares relacionadas con los tratamientos del cáncer. La cardio-oncología surge como subespecialidad dentro de cardiología, con el objetivo de desarrollar estrategias multidisciplinares de promoción, prevención y tratamiento de las alteraciones cardiovasculares en pacientes oncológicos en los diferentes niveles asistenciales y en colaboración con fundaciones y asociaciones de pacientes. Dentro de esta colaboración inter-especialidades, la Salud Laboral, a través de los médicos y enfermeros del trabajo que integran las Unidades Básicas sanitarias de los servicios de prevención, participa realizando, desde el ámbito laboral, el seguimiento y control de los trabajadores que han sido tratados de cáncer. El análisis de los riesgos del puesto, la vigilancia sanitaria específica y el análisis de la documentación clínica deben permitir a los especialistas determinar las limitaciones y capacidades residuales y valorar la aptitud para el trabajo de los pacientes oncológicos, para actuar en prevención y control de estas patologías. El grupo de cardio-onco-hematologia laboral presenta la Guía para el manejo coordinado de los trabajadores con cáncer y riesgo cardiovascular con el objetivo de ofrecer apoyo al profesional sanitario en el abordaje preventivo del riesgo cardiovascular en aquellas personas que, tras recibir tratamiento por un proceso oncológico se reincorporan al mundo laboral, y en los que se ha de realizar una valoración global y coordinada por: oncología, cardiología, hematología y los especialistas de las unidades básicas de Salud Laboral

Cardiovascular diseases and cancer share risk factors and are the main causes of mortality and morbidity in our environment. On the other hand, the concept of cardiotoxicity refers to the development of cardiovascular pathologies related to cancer treatments. Cardio-oncology emerges as a subspecialty within cardiology, with the objective of developing multidisciplinary strategies for the promotion, prevention and treatment of cardiovascular disorders in cancer patients at different care levels and in collaboration with foundations and patient associations. Within this inter-specialties collaboration, Occupational Health, through the labour doctors and nurses that make up the Basic Health Units of the prevention services, participates by carrying out, from the workplace, the monitoring and control of the workers who have been treated for cancer. The risks position analysis, the specific sanitary surveillance and the clinical documentation analysis must allow the specialists to determine the limitations and residual capacities and assess the aptitude for the work of the oncological patients, to act in prevention and control of these pathologies. The labor cardio-onco-hematology group presents the Guide for the coordinated management of workers with cancer and cardiovascular risk with the aim of offering support to the healthcare professional in the preventive approach of cardiovascular risk in those who, after receiving treatment for a The oncological process is reincorporated into the world of work, and in which a global assessment must be carried out and coordinated by: oncology, cardiology, hematologic and the specialists of the basic units of Occupational Health

In vitro determination of the short-chain synthetic peptide RP13 antimicrobial activity.

BACKGROUND: The proliferation of antibiotic-resistant microorganisms, along with the lack of new drugs against them, has elicited the interest of the scientific community on the study and development of endogenous synthetic compounds with bacteriostatic or bactericidal activity. In recent years, several short-chain, low molecular weight peptides isolated from natural sources such as plants and animals have demonstrated an array of antimicrobial activities. Despite having structural characteristics similar to microbicidal peptides isolated from human platelets, peptide RP11 does not exhibit antimicrobial activity. OBJECTIVE: In vitro determination of the antimicrobial activity of the synthetic peptide RP13. MATERIAL AND METHODS: Peptide RP13 was prepared modifying the original amino acids sequence of peptide RP11, reversing the position of the amino acids lysine and tyrosine in order to modify the conformation of the original peptide. These amino acids are localized close to the N-terminus of the peptidic chain. Peptide RP13 was prepared in solution using conventional methods for peptide synthesis. The antimicrobial activity of RP13 was assessed against the microorganisms S. aureus, E. faecalis and E. coli in a test solution and later evaluated by cultivation of plates during the first 2 h after inoculation of bacteria. RP13 activity antimicrobial was compared against tetracycline, a broad-spectrum antibiotic. RESULTS: The new peptide RP13, resulting form the structural modification of the amino acid sequence of peptide RP11, displayed antimicrobial activity. RP13 demonstrated to be more efficient inhibiting the growth of gram-positive than gramnegative bacteria. CONCLUSIONS: The structural modification of peptide RP11, obtained from human platelets, resulted in a new peptide with improved antimicrobial activity. These results clearly demonstrate that peptides of natural origin, as well as their synthetic analogs, represent an attractive alternative against pathogenic agents.